Advocacy at a Glance
November 11, 2016
Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA.
- Mr. Trump, the Election and FDA. Relying on a number of sources, it appears that President-Elect Donald Trump did not personally speak about the FDA during his campaign. That is not surprising, giving the high level of the campaign. But we do know that he is especially focused on jobs and growing the economy. Beyond its important public health work, the Alliance has long explained the importance that FDA plays in the economy — regulating products that are 20% of the US consumer spending. The industries that are regulated by FDA have high-paying jobs, and there is both consumer and industry support for an agency that is resourced so that it can make science-based decisions. We look forward to working with the Trump Administration to explain the importance of FDA’s work, and how that work can benefit both the public health and the US economy. The theme of FDA and the incoming Administration is explored further in this week’s Analysis and Commentary.
- Alliance Annual Member Meeting/2016 Election Re-Cap/Transition Process is Tuesday, November 15 at 1 p.m. This year, we will be repeating our very successful post-election analysis by the bipartisan political leadership team at Akin Gump. Former Senator Kay Hagan (D, NC), Former Congressman Vic Fazio (D, CA), former Congressman Tom Loeffler (R, TX), and longtime Republican insider Jamie Tucker will provide their perspective on the election result. Please let Lynnette Bechtel know if you will be joining.
- Lame Duck Spending Deal? When Congress returns next week, we will start to get clarity on whether government funding for FY 17 will be by Continuing Resolution (through March, probably) or some variant of an Omnibus appropriations bill (through the end of FY 17). The head of the conservative House Republican Study Committee has called for a short-term CR. Senate Majority Leader McConnell has expressed a preference for a year-long appropriations package.
- Alliance Meetings with FDA Planned for November. We have a meeting at White Oak planned with Dr. Rachel Sherman, Deputy Commissioner for Medical Products and Tobacco, on November 15 in the morning. We also have a meeting scheduled with Dr. Peter Marks, new Director of the CBER, in the morning on November 16. Let Lynnette know if you are interested in joining either meeting.